Home / Insurance / Does Tricare Cover Wegovy? Insurance Guide 2026
MC
Reviewed by Marcus Chen Updated February 20, 2026

Does Tricare Cover Wegovy? Insurance Guide 2026

Bold opening

In 2026, many Tricare beneficiaries are asking whether their insurance covers Wegovy, the once-weekly injectable semaglutide approved for chronic weight management and type 2 diabetes. As obesity and diabetes rates rise among military families, understanding Tricare’s stance on Wegovy is critical. This guide provides evidence-based answers on Wegovy coverage, costs, prior authorization, and appeal strategies under Tricare Prime, Select, and other plans. Whether you’re seeking Wegovy for weight loss or diabetes, this article will help you navigate the process and explore alternatives if coverage is denied.

Does Tricare Cover Wegovy for Diabetes?

Tricare’s coverage of Wegovy for type 2 diabetes depends on the specific formulation and clinical justification. Wegovy (semaglutide 2.4 mg) is FDA-approved for chronic weight management, while its lower-dose counterpart, Ozempic (semaglutide 0.5–2 mg), is approved for glycemic control in diabetes. Tricare typically covers Ozempic for diabetes under its pharmacy benefit, but Wegovy may not be automatically approved for this indication unless the patient meets specific criteria, such as a BMI ≥ 27 kg/m² with weight-related comorbidities.

A 2023 study in Diabetes Care demonstrated that semaglutide significantly improves HbA1c and reduces cardiovascular risk in patients with type 2 diabetes. However, Tricare may require prior authorization to confirm that Wegovy is medically necessary for diabetes management, particularly if the patient has failed first-line therapies like metformin. Providers must document inadequate glycemic control despite lifestyle modifications and other antidiabetic agents. If Wegovy is prescribed off-label for diabetes, Tricare may deny coverage, leaving beneficiaries to pay out-of-pocket or appeal the decision.

Does Tricare Cover Wegovy for Weight Loss?

Tricare’s coverage of Wegovy for weight loss is contingent on strict clinical criteria. Wegovy is FDA-approved for chronic weight management in adults with a BMI ≥ 30 kg/m² or ≥ 27 kg/m² with at least one weight-related comorbidity (e.g., hypertension, dyslipidemia, or obstructive sleep apnea). Tricare generally aligns with these guidelines but requires prior authorization to verify eligibility.

A 2021 New England Journal of Medicine study found that Wegovy led to an average 15% reduction in body weight over 68 weeks, outperforming lifestyle interventions alone. However, Tricare may deny coverage if the patient has not first attempted structured diet and exercise programs for at least six months. Additionally, Tricare may limit Wegovy coverage to beneficiaries enrolled in a comprehensive weight management program, such as those offered through military treatment facilities or Tricare-approved providers. Without prior authorization, Wegovy is unlikely to be covered, and beneficiaries may face high out-of-pocket costs.

How Much Does Wegovy Cost With Tricare?

The cost of Wegovy with Tricare varies based on the beneficiary’s plan, formulary tier, and whether prior authorization is approved. Without insurance, Wegovy retails for approximately $1,300–$1,500 per month. Under Tricare, beneficiaries with approved coverage typically pay a tiered copayment: $0–$34 for generic medications, $29–$69 for preferred brand-name drugs, and $69 or more for non-preferred brands. Wegovy is classified as a non-preferred brand under most Tricare formularies, placing it in the highest copay tier.

For example, Tricare Prime beneficiaries may pay a $69 copay per month for Wegovy if it is approved, while Tricare Select enrollees could face higher costs, particularly if they use a non-network pharmacy. A 2024 analysis in JAMA Network Open highlighted that high out-of-pocket costs for GLP-1 agonists like Wegovy contribute to medication nonadherence. Beneficiaries should verify their specific copay through the Tricare Pharmacy Program or their regional contractor (e.g., Express Scripts). If Wegovy is denied, the full retail price applies, though manufacturer savings programs (e.g., NovoCare) may reduce costs for eligible patients.

Wegovy Prior Authorization for Tricare

Obtaining prior authorization for Wegovy through Tricare requires thorough documentation from the prescribing provider. Tricare’s prior authorization process for Wegovy is designed to ensure the medication is used appropriately for FDA-approved indications. Providers must submit evidence of the patient’s BMI, weight-related comorbidities, and failure of non-pharmacologic interventions (e.g., diet, exercise, or behavioral therapy).

A 2022 study in Obesity found that prior authorization requirements for weight-loss medications like Wegovy reduce inappropriate prescribing but may delay access for eligible patients. Tricare’s prior authorization form for Wegovy typically requires:

  1. Documentation of BMI ≥ 30 kg/m² or ≥ 27 kg/m² with comorbidities.
  2. Proof of participation in a structured weight management program for at least six months.
  3. Evidence of failed weight loss with lifestyle modifications alone.
  4. Laboratory results (e.g., HbA1c, lipid panel) to support medical necessity.

Providers can submit prior authorization requests electronically through the Tricare Pharmacy Program portal or via fax. Approval timelines vary but generally take 3–10 business days. If denied, beneficiaries can appeal the decision with additional supporting documentation.

How to Get Tricare to Cover Wegovy

Securing Tricare coverage for Wegovy requires a strategic approach, beginning with a clear understanding of Tricare’s criteria and proactive communication with your provider. First, confirm that you meet the clinical requirements for Wegovy: a BMI ≥ 30 kg/m² or ≥ 27 kg/m² with weight-related comorbidities. If you have type 2 diabetes, ensure your provider prescribes Wegovy for its approved indication or documents off-label use with strong justification.

Next, work with your provider to gather the necessary documentation for prior authorization. This includes:

  • A detailed medical history highlighting weight-related conditions (e.g., hypertension, sleep apnea).
  • Records of failed weight loss attempts through diet, exercise, or other non-pharmacologic interventions.
  • Laboratory results (e.g., HbA1c, lipid panel) to demonstrate medical necessity.

A 2023 Journal of Managed Care & Specialty Pharmacy study emphasized that providers who submit comprehensive prior authorization requests are more likely to secure coverage for GLP-1 agonists like Wegovy. If your initial request is denied, request a peer-to-peer review with a Tricare clinical pharmacist. Additionally, consider enrolling in a Tricare-approved weight management program, as participation may strengthen your case for Wegovy coverage.

What to Do If Tricare Denies Wegovy

If Tricare denies coverage for Wegovy, beneficiaries have several options to appeal the decision or explore alternatives. The first step is to request a detailed explanation of the denial from Tricare, which will outline the specific reasons for rejection (e.g., lack of medical necessity, failure to meet BMI criteria). A 2024 Health Affairs study found that 40% of prior authorization denials for weight-loss medications are overturned on appeal, underscoring the importance of persistence.

To appeal, submit a reconsideration request within 90 days of the denial. Include:

  1. A letter from your provider explaining why Wegovy is medically necessary.
  2. Additional documentation, such as updated lab results or records of failed weight loss attempts.
  3. A peer-reviewed study supporting Wegovy’s efficacy for your condition (e.g., the STEP trials for weight loss or SUSTAIN trials for diabetes).

If the reconsideration is denied, you can escalate the appeal to an independent review organization (IRO). Tricare contracts with third-party IROs to review appeals objectively. While the process can take 30–60 days, it provides another opportunity to secure coverage. In the meantime, explore manufacturer savings programs (e.g., NovoCare) or clinical trials for Wegovy to reduce out-of-pocket costs.

Tricare Alternatives If Wegovy Is Not Covered

If Tricare denies coverage for Wegovy, several alternatives may be available, depending on your clinical needs and budget. For weight loss, other FDA-approved medications like phentermine, liraglutide (Saxenda), or bupropion/naltrexone (Contrave) may be covered under Tricare’s formulary. A 2023 meta-analysis in The Lancet found that liraglutide and Wegovy have comparable efficacy for weight loss, though Wegovy demonstrated slightly greater reductions in body weight.

For type 2 diabetes, Tricare covers several GLP-1 agonists, including Ozempic (semaglutide), Trulicity (dulaglutide), and Victoza (liraglutide). These medications may be more accessible and cost-effective than Wegovy, particularly if prior authorization is not required. Additionally, Tricare beneficiaries can explore lifestyle modification programs through military treatment facilities or Tricare-approved providers. Programs like the MOVE! Weight Management Program (offered by the VA and some military hospitals) provide structured support for diet, exercise, and behavioral therapy.

If cost is a barrier, consider:

  • Manufacturer savings programs (e.g., NovoCare for Wegovy or Saxenda).
  • Clinical trials for weight-loss medications (e.g., through ClinicalTrials.gov).
  • Mail-order pharmacies or discount programs (e.g., GoodRx) to reduce out-of-pocket expenses.

Frequently Asked Questions

Does Tricare cover Wegovy for weight loss?

Tricare may cover Wegovy for weight loss if you meet specific criteria, including a BMI ≥ 30 kg/m² or ≥ 27 kg/m² with weight-related comorbidities, and documentation of failed lifestyle interventions. Prior authorization is required, and coverage is not guaranteed. A 2023 Obesity study found that Tricare’s prior authorization process for Wegovy reduces inappropriate prescribing but may limit access for eligible patients.

How much is the Wegovy copay with Tricare?

The Wegovy copay with Tricare depends on your plan and formulary tier. For Tricare Prime beneficiaries, the copay is typically $69 per month if Wegovy is approved as a non-preferred brand. Tricare Select enrollees may face higher costs, particularly if using a non-network pharmacy. Without coverage, Wegovy costs approximately $1,300–$1,500 per month, though manufacturer savings programs may reduce expenses.

Can I appeal if Tricare denies Wegovy?

Yes, you can appeal a Tricare denial for Wegovy by submitting a reconsideration request within 90 days. Include a provider letter, additional documentation, and peer-reviewed studies supporting Wegovy’s efficacy. If the reconsideration is denied, you can escalate the appeal to an independent review organization. A 2024 Health Affairs study found that 40% of prior authorization denials for weight-loss medications are overturned on appeal.

Disclaimer from Marcus Chen, PharmD: The information provided in this article is for educational purposes only and does not constitute medical or legal advice. Tricare’s coverage policies for Wegovy may change, and beneficiaries should verify their specific benefits with Tricare or their regional contractor. Always consult your healthcare provider before starting or discontinuing any medication.